Biohaven Ltd.
BHVN NYSE· Pharmaceutical Preparations
Last close · Oct 23, 2026
$13.88
KIRA · Stoqly’s AI analyst, in plain words
- Biohaven Ltd. lost $739M in fiscal 2025.
- Free cash flow was −$610M in fiscal 2025, — of revenue.
Market cap
$2.1B
P/E
—
Revenue
—
Net income
−$739M
Free cash flow
−$610M
Operating margin
—
Biohaven Ltd. in 30 seconds · fiscal 2025
Does it make a profit?
−$739M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Biohaven Ltd. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 2, 2026
- Legal name
- Biohaven Ltd.
- CIK
- 0001935979
Biohaven Ltd. · BHVN
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$214M | −$570M | −$408M | −$846M | −$739M |
| Diluted EPS | −$5.43 | −$12.75 | −$5.73 | −$9.28 | −$6.86 |
| Cash | |||||
| Cash from operations | −$146M | −$298M | −$332M | −$582M | −$609M |
| Capital expenditure | $0.9M | $6.1M | $3.0M | $4.0M | $0.7M |
| Free cash flow | −$147M | −$304M | −$335M | −$587M | −$610M |
| Share count change | 0.0% | 13.6% | 59.1% | 28.1% | 18.0% |
| Debt and strength | |||||
| Cash and short-term investments | $76.1M | $465M | $382M | $486M | $319M |
| Shareholders' equity | $34.7M | $539M | $428M | $423M | $52.1M |
| Current ratio | 2.3x | 6.5x | 8.0x | 3.5x | 3.2x |
| Returns and quality | |||||
| Return on equity | −830.7% | −198.9% | −84.4% | −198.8% | −310.8% |
| Return on tangible equity | −1,434.8% | −109.9% | −100.0% | −209.7% | −2,288.7% |
| Altman Z'' | −7.1 | 3.3 | 1.3 | −10.4 | −22.3 |
Insiders bought, 12 months
$30.6M
4 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Biohaven Ltd. · BHVN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $13.88 a share, the company is worth $2.1B.
Source: SEC EDGAR XBRL filings (CIK 0001935979). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.